TDRD6

Summary

TDRD6 (tudor domain containing 6, HGNC:21339) is a protein-coding gene on chromosome 6p12.3, encoding Tudor domain-containing protein 6 (O60522). Tudor domain-containing protein involved in germ cell development, more specifically the formation of chromatoid body (during spermiogenesis), Balbiani body (during oogenesis), germ plasm (upon fertilization), and for proper miRNA expression and spliceosome maturation.

This gene encodes a tudor domain-containing protein and component of the chromatoid body, a type of ribonucleoprotein granule present in male germ cells. Studies in rodents have demonstrated a role for the encoded protein in spermiogenesis and the nonsense mediated decay (NMD) pathway. This protein is a major autoantigen in human patients with autoimmune polyendocrine syndrome type 1 (APS1).

Source: NCBI Gene 221400 — RefSeq curated summary.

At a glance

• Gene–disease (curated): male infertility with azoospermia or oligozoospermia due to single gene mutation (Moderate, GenCC) — +2 more curated relationships
• Clinical variants (ClinVar): 399 total
• MANE Select transcript: NM_001010870

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:21339
Approved symbol	TDRD6
Name	tudor domain containing 6
Location	6p12.3
Locus type	gene with protein product
Status	Approved
Aliases	NY-CO-45, bA446F17.4, CT41.2, SPATA36
Ensembl gene	ENSG00000180113
Ensembl biotype	protein_coding
OMIM	611200
Entrez	221400

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 protein_coding

ENST00000316081, ENST00000450697, ENST00000544460

RefSeq mRNA: 2 — MANE Select: NM_001010870 NM_001010870, NM_001168359

CCDS: CCDS34470, CCDS55017

Canonical transcript exons

ENST00000316081 — 4 exons

Exon	Start	End
ENSE00001426271	46695821	46695945
ENSE00001454977	46697998	46698087
ENSE00001454981	46687885	46694174
ENSE00002269224	46701858	46704319

Expression profiles

Bgee: expression breadth ubiquitous, 199 present calls, max score 98.39.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.0403 / max 30.6738, expressed in 7 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
68136	0.0198	4
68135	0.0116	3
68137	0.0088	5

Top tissues by expression

249 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	98.39	gold quality
oocyte	CL:0000023	97.24	gold quality
sperm	CL:0000019	95.99	gold quality
right testis	UBERON:0004534	92.23	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	91.84	gold quality
left testis	UBERON:0004533	91.36	gold quality
testis	UBERON:0000473	90.13	gold quality
cerebellar hemisphere	UBERON:0002245	88.94	gold quality
cerebellar cortex	UBERON:0002129	88.80	gold quality
right hemisphere of cerebellum	UBERON:0014890	88.13	gold quality
cerebellum	UBERON:0002037	87.79	gold quality
tendon of biceps brachii	UBERON:0008188	87.50	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	87.27	gold quality
mucosa of stomach	UBERON:0001199	81.10	gold quality
adult organism	UBERON:0007023	77.83	gold quality
Brodmann (1909) area 23	UBERON:0013554	77.76	gold quality
primary visual cortex	UBERON:0002436	77.19	gold quality
right lobe of liver	UBERON:0001114	76.74	gold quality
medial globus pallidus	UBERON:0002477	76.58	gold quality
middle temporal gyrus	UBERON:0002771	75.98	silver quality
germinal epithelium of ovary	UBERON:0001304	75.62	gold quality
Brodmann (1909) area 9	UBERON:0013540	75.29	gold quality
cerebellar vermis	UBERON:0004720	74.92	gold quality
tibia	UBERON:0000979	74.81	gold quality
adenohypophysis	UBERON:0002196	74.80	gold quality
caudate nucleus	UBERON:0001873	74.76	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	74.69	gold quality
apex of heart	UBERON:0002098	74.66	gold quality
epithelial cell of pancreas	CL:0000083	74.57	gold quality
right lobe of thyroid gland	UBERON:0001119	74.51	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.14

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

107 targeting TDRD6, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-1229-3P	99.97	66.49	906
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-6753-3P	99.93	66.57	637
HSA-MIR-7107-3P	99.93	66.73	627
HSA-MIR-145-5P	99.92	71.13	1836
HSA-MIR-5195-3P	99.92	70.92	1877
HSA-MIR-8063	99.91	69.76	3146
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-30A-3P	99.87	69.74	2928
HSA-MIR-30D-3P	99.87	69.92	2917

Literature-anchored findings (GeneRIF, showing 2)

• Whole-exome sequencing results in a patient with oligoasthenoteratozoospermia (OAT) from a consanguineous family identified a rare homozygous variant in TDRD6 which co-segregated with the OAT phenotype. (PMID:29551503)
• Bi-allelic variants in chromatoid body protein TDRD6 cause spermiogenesis defects and severe oligoasthenoteratozoospermia in humans. (PMID:38341271)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	tdrd6a	ENSDARG00000070052
danio_rerio	tdrd6b	ENSDARG00000089954
mus_musculus	Tdrd6	ENSMUSG00000040140
rattus_norvegicus	Tdrd6	ENSRNOG00000025693
drosophila_melanogaster	tud	FBGN0003891

Paralogs (6): TDRD1 (ENSG00000095627), TDRD5 (ENSG00000162782), TDRD10 (ENSG00000163239), TDRKH (ENSG00000182134), TDRD7 (ENSG00000196116), TDRD15 (ENSG00000218819)

Protein

Protein identifiers

Tudor domain-containing protein 6 — O60522 (reviewed: O60522)

Alternative names: Antigen NY-CO-45, Cancer/testis antigen 41.2

All UniProt accessions (2): H0Y590, O60522

UniProt curated annotations — full annotation on UniProt →

Function. Tudor domain-containing protein involved in germ cell development, more specifically the formation of chromatoid body (during spermiogenesis), Balbiani body (during oogenesis), germ plasm (upon fertilization), and for proper miRNA expression and spliceosome maturation. Essential for RNA-dependent helicase UPF1 localization to chromatoid body, for UPF1-UPF2 and UPF1-DDX4 interactions which are required for mRNA degradation, using the extended 3’ UTR-triggered nonsense-mediated mRNA decay (NMD) pathway. Involved in spliceosome maturation and mRNA splicing in prophase I spermatocytes through interaction with arginine N-methyltransferase PRMT5 and symmetrically arginine dimethylated SNRPB (small nuclear ribonucleoprotein-associated protein).

Subunit / interactions. Found in a mRNP complex (i.e. messenger ribonucleoproteins which correspond to mRNA with bound proteins), at least composed of TDRD1, TDRD6, TDRD7 and DDX4. Found in a complex, at least composed of PIWIL1, PIWIL2, DDX4 and TDRD6. Interacts with Tex19.1 and probably Tex19.2. Interacts with PRMT5. Interacts with SNRPB (when methylated); to trigger spliceosome formation.

Subcellular location. Cytoplasm.

Post-translational modifications. Undergoes proteolytic cleavage near the C-terminal by an unknown protease during the transition from meiosis I to meiosis II in primary spermatocytes.

Domain organisation. The tudor domains recognize and bind to proteins with dimethylated arginine residues.

Isoforms (2)

UniProt ID	Names	Canonical?
O60522-1	1	yes
O60522-2	2

RefSeq proteins (2): NP_001010870, NP_001161831 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002999	Tudor	Domain
IPR035437	SNase_OB-fold_sf	Homologous_superfamily
IPR047444	Tudor_TDRD6_rpt1	Domain
IPR047445	Tudor_TDRD6_rpt2	Domain
IPR047446	Tudor_TDRD6_rpt4	Domain
IPR047447	Tudor_TDRD6_rpt3	Domain
IPR050621	Tudor_domain_containing	Family

Pfam: PF00567

UniProt features (23 total): domain 8, sequence variant 4, sequence conflict 4, modified residue 3, chain 1, compositionally biased region 1, splice variant 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O60522-F1	64.82	0.12

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 293, 1722, 2062

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-5601884	PIWI-interacting RNA (piRNA) biogenesis
R-HSA-211000	Gene Silencing by RNA
R-HSA-74160	Gene expression (Transcription)

MSigDB gene sets: 74 (showing top): GOBP_AXIS_SPECIFICATION, GOBP_EMBRYONIC_AXIS_SPECIFICATION, GOBP_OOGENESIS, GOBP_MALE_GAMETE_GENERATION, GOBP_ANATOMICAL_STRUCTURE_MATURATION, chr6p12, GOBP_ANTERIOR_POSTERIOR_PATTERN_SPECIFICATION, GOBP_CELL_MATURATION, GOBP_EMBRYONIC_PATTERN_SPECIFICATION, GOBP_SEGMENTATION, GOBP_CELLULAR_PROCESS_INVOLVED_IN_REPRODUCTION_IN_MULTICELLULAR_ORGANISM, GOBP_OOCYTE_DIFFERENTIATION, GOBP_BLASTODERM_SEGMENTATION, GOBP_PIRNA_PROCESSING, GOBP_FEMALE_GAMETE_GENERATION

GO Biological Process (4): spermatogenesis (GO:0007283), P granule organization (GO:0030719), piRNA processing (GO:0034587), cell differentiation (GO:0030154)

GO Molecular Function (0):

GO Cellular Component (3): cytoplasm (GO:0005737), chromatoid body (GO:0033391), P granule (GO:0043186)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Gene Silencing by RNA	1
Gene expression (Transcription)	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoplasmic ribonucleoprotein granule	2
developmental process involved in reproduction	1
male gamete generation	1
organelle organization	1
pole plasm assembly	1
regulatory ncRNA processing	1
cellular developmental process	1
intracellular anatomical structure	1
cellular anatomical structure	1
germ plasm	1

Protein interactions and networks

STRING

888 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TDRD6	PIWIL1	Q96J94	931
TDRD6	PIWIL2	Q8TC59	857
TDRD6	DDX25	Q9UHL0	715
TDRD6	TDRD9	Q8NDG6	673
TDRD6	MAEL	Q96JY0	620
TDRD6	PIWIL4	Q7Z3Z4	619
TDRD6	TDRD7	Q8NHU6	602
TDRD6	TDRD1	Q9BXT4	592
TDRD6	TDRD12	Q587J7	588
TDRD6	PRMT5	O14744	525
TDRD6	DDX4	Q9NQI0	503
TDRD6	PLD6	Q8N2A8	489
TDRD6	MOV10L1	Q9BXT6	462
TDRD6	TDRD3	Q9H7E2	451
TDRD6	SPATA19	Q7Z5L4	443

IntAct

3 interactions, top by confidence:

A	B	Type	Score
TDRD6	MYH10	psi-mi:“MI:0915”(physical association)	0.400
M		psi-mi:“MI:0914”(association)	0.350

BioGRID (8): TDRD6 (Affinity Capture-MS), MYH10 (Proximity Label-MS), TDRD6 (Affinity Capture-MS), AP1M1 (Cross-Linking-MS (XL-MS)), NOM1 (Cross-Linking-MS (XL-MS)), TDRD6 (Protein-RNA), TDRD6 (Affinity Capture-MS), TDRD6 (Affinity Capture-MS)

ESM2 similar proteins: A0JM98, A1L1H3, A6NAF9, A6QLE1, A9CPT4, B5MCY1, D2H0H6, D2H3M0, D4A7V9, E1BPH3, E1C3S7, E2QTD3, E2RDV1, E7FDW8, F1R237, O60522, P57075, P61407, P97874, Q14B46, Q1L981, Q4R3G4, Q58EK5, Q5DTW2, Q5JTW2, Q5M7P8, Q5RAH6, Q5VCS6, Q5VZ19, Q5XGX5, Q61846, Q68DX3, Q6NU04, Q80VK6, Q8K1H1, Q8NAT2, Q8NHU6, Q90WE3, Q99KY4, Q99MV1

Diamond homologs: F1R237, O60522, P61407, Q14BI7, Q80VL1, Q8NDG6, Q9W0S7, E7FDW8, Q66X93, Q78PY7, Q863B3, Q90WE3, Q9VQ91, Q5REU4, Q7KZF4, Q7ZT42, Q8VZG7, Q99MV1, Q9BXT4, Q9FLT0, Q9Y7U7, Q99MV7, P25823, A4RMK0, A9CPT4, Q9BXT8, H9JD76, Q00341, Q5M7P8, Q5R439, Q8VDJ3, Q9Z1A6

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

399 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	357
Likely benign	33
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

409 predictions. Top by Δscore:

Variant	Effect	Δscore
6:46698083:CTGAG:C	donor_loss	1.0000
6:46698084:TGAG:T	donor_loss	1.0000
6:46698089:T:A	donor_loss	1.0000
6:46695815:T:TA	acceptor_gain	0.9900
6:46695819:A:AG	acceptor_gain	0.9900
6:46695820:G:GG	acceptor_gain	0.9900
6:46697992:CTGTA:C	acceptor_loss	0.9900
6:46697993:TGTAG:T	acceptor_loss	0.9900
6:46697994:GTAG:G	acceptor_loss	0.9900
6:46697995:TAGGT:T	acceptor_loss	0.9900
6:46697996:A:AC	acceptor_loss	0.9900
6:46700357:A:G	acceptor_gain	0.9900
6:46701856:A:AG	acceptor_gain	0.9900
6:46701857:G:GG	acceptor_gain	0.9900
6:46701857:GAAAA:G	acceptor_gain	0.9900
6:46697996:A:AG	acceptor_gain	0.9800
6:46697997:G:GG	acceptor_gain	0.9800
6:46700356:A:AG	acceptor_gain	0.9800
6:46701857:GAA:G	acceptor_gain	0.9800
6:46701857:GAAA:G	acceptor_gain	0.9800
6:46698071:A:G	donor_gain	0.9700
6:46701855:CAGAA:C	acceptor_loss	0.9700
6:46701856:A:AT	acceptor_loss	0.9700
6:46701857:G:GC	acceptor_loss	0.9700
6:46701857:GA:G	acceptor_gain	0.9700
6:46694171:TCAGG:T	donor_loss	0.9600
6:46694175:G:GA	donor_loss	0.9600
6:46694176:T:A	donor_loss	0.9600
6:46695815:TGGCA:T	acceptor_gain	0.9600
6:46695816:GGCAG:G	acceptor_gain	0.9600

AlphaMissense

13801 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:46689962:T:A	W612R	0.998
6:46689962:T:C	W612R	0.998
6:46689632:T:C	F502L	0.997
6:46689634:T:A	F502L	0.997
6:46689634:T:G	F502L	0.997
6:46689290:T:A	W388R	0.996
6:46689290:T:C	W388R	0.996
6:46689633:T:C	F502S	0.996
6:46689964:G:C	W612C	0.996
6:46689964:G:T	W612C	0.996
6:46688375:C:A	R83S	0.995
6:46689112:A:C	R328S	0.995
6:46689112:A:T	R328S	0.995
6:46689926:T:C	C600R	0.995
6:46690097:A:C	S657R	0.995
6:46690099:T:A	S657R	0.995
6:46690099:T:G	S657R	0.995
6:46689111:G:C	R328T	0.994
6:46690125:C:A	A666D	0.994
6:46690633:A:C	R835S	0.994
6:46690633:A:T	R835S	0.994
6:46689987:T:C	F620S	0.993
6:46690124:G:C	A666P	0.993
6:46691281:G:C	R1051S	0.993
6:46691281:G:T	R1051S	0.993
6:46693173:T:A	V1682D	0.993
6:46689111:G:T	R328I	0.992
6:46689790:G:C	R554S	0.992
6:46689790:G:T	R554S	0.992
6:46689846:G:A	G573D	0.992

dbSNP variants (sampled 300 via entrez): RS1000212789 (6:46698263 T>C), RS1000292088 (6:46703376 G>A), RS1000353967 (6:46701226 A>G), RS1000481608 (6:46700794 A>T), RS1000527118 (6:46694864 T>A), RS1000786232 (6:46686111 C>A), RS1001349522 (6:46699657 CAAAG>C), RS1001440397 (6:46679329 G>A), RS1001486353 (6:46699291 A>G), RS1001760566 (6:46687989 C>G,T), RS1001904745 (6:46682937 C>A), RS1002149553 (6:46694481 A>G), RS1002355325 (6:46698297 G>A), RS1002369552 (6:46701752 C>A,G,T), RS1002539090 (6:46698879 A>G,T)

Disease associations

OMIM: gene MIM:611200 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
male infertility with azoospermia or oligozoospermia due to single gene mutation	Moderate	Autosomal recessive
oligospermia	Limited	Autosomal recessive
schizophrenia	Limited	Autosomal dominant

Mondo (4): long QT syndrome (MONDO:0002442), oligospermia (MONDO:0001913), schizophrenia (MONDO:0005090), (MONDO:0018393)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D008133	Long QT Syndrome	C14.280.067.565; C14.280.123.625; C16.131.240.400.715; C23.550.073.547
D009845	Oligospermia	C12.100.500.430.508; C12.100.750.700.508; C12.200.294.430.508

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs2270450	SLC25A27, TDRD6		0.00	0

CTD chemical–gene interactions

17 total (human), top 17 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases methylation, affects cotreatment, increases expression	3
Nickel	decreases expression	2
bisphenol A	decreases methylation	1
trichostatin A	increases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
Benzo(a)pyrene	increases expression	1
Cadmium	decreases expression, increases abundance	1
Malathion	increases expression	1
Thimerosal	increases expression	1
Tobacco Smoke Pollution	affects expression	1
Tretinoin	increases expression	1
Cyclosporine	decreases expression	1
Aflatoxin B1	affects expression	1
Cadmium Chloride	decreases expression, increases abundance	1
Permethrin	decreases methylation, increases expression	1

Clinical trials (associated diseases)

366 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT02307994	PHASE4	UNKNOWN	Clinical Research on Effectiveness and Safety of Treatment of Severe Oligospermia or Azoospermia With uFSH
NCT05320536	PHASE4	UNKNOWN	A Clinical Study of Gulingji Capsule in the Treatment of Idiopathic Oligospermia, Asthenia, and Teratozoospermia
NCT06260007	PHASE4	RECRUITING	Efficacy and Safety Study of Products Based on Tribulus Terrestris, L. in Men With Oligospermia
NCT00000374	PHASE4	COMPLETED	Treatment for First-Episode Schizophrenia
NCT00001656	PHASE4	COMPLETED	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00007774	PHASE4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT00018668	PHASE4	COMPLETED	Antipsychotic Response in Schizophrenia
NCT00034801	PHASE4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00034905	PHASE4	COMPLETED	A Comparison of Seroquel vs. Risperidone in Schizophrenia
NCT00036088	PHASE4	COMPLETED	Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT00044187	PHASE4	COMPLETED	The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044655	PHASE4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048828	PHASE4	COMPLETED	Treating Drug-Resistant Childhood Schizophrenia
NCT00053703	PHASE4	COMPLETED	Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
NCT00056498	PHASE4	COMPLETED	Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00061802	PHASE4	COMPLETED	Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00080327	PHASE4	COMPLETED	Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00088049	PHASE4	COMPLETED	Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00090012	PHASE4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00100776	PHASE4	COMPLETED	Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00103571	PHASE4	COMPLETED	Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00108368	PHASE4	COMPLETED	The Effects of Risperidone and Olanzapine on Thinking
NCT00114595	PHASE4	COMPLETED	Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
NCT00130923	PHASE4	COMPLETED	Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCT00137020	PHASE4	COMPLETED	Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
NCT00140166	PHASE4	COMPLETED	Treatment of Acute Schizophrenia With Vitamin Therapy
NCT00145847	PHASE4	COMPLETED	Naltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00148564	PHASE4	COMPLETED	Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00156715	PHASE4	COMPLETED	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00158223	PHASE4	COMPLETED	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
NCT00159081	PHASE4	COMPLETED	One Year Drug Treatment in First-Episode Schizophrenia
NCT00159120	PHASE4	COMPLETED	Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159133	PHASE4	COMPLETED	Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
NCT00159757	PHASE4	TERMINATED	12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT00167817	PHASE4	COMPLETED	Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00169026	PHASE4	TERMINATED	Alcoholism and Schizophrenia: Effects of Clozapine
NCT00169039	PHASE4	TERMINATED	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169065	PHASE4	COMPLETED	Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00169091	PHASE4	TERMINATED	Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia